

# IUS in post surgical patients

## Kerri Novak

Assoc. Professor of Medicine  
Deputy Division Head, Division of Gastroenterology &  
Hepatology  
Foothills Medical Centre  
University of Calgary  
Calgary, Canada



Kuwait City, Kuwait, November 21<sup>st</sup> – 22<sup>nd</sup>, 2025

# Intended Learning Outcomes

By the end of this session, the learner will be able to:

1. Evaluate post-operative anastomoses using appropriate imaging techniques (e.g., transabdominal ultrasound) and interpret findings to identify recurrence of inflammation at the anastomotic site.
2. Identify anatomical variations or abnormalities (e.g., altered surgical anatomy, skip lesions, adhesions, altered bowel loops position) that could modify the typical localization of bowel segments on IUS and impact the interpretation of findings in the post-operative setting.

# Faculty Disclosure

**Speaker:** Janssen, Abbvie, Takeda, Pfizer

**Advisory boards:** Janssen, Abbvie, Takeda, Eli Lilly, Pfizer, Ferring, Amgen, Fresenius Kabi, Celltrion, Bristol Myers Squibb

**Research Support:** Helmsley Trust, DOVA health, Janssen





# Monitoring post operative Crohn's disease – does it matter?

- Up to 90% of patients exhibit endoscopic disease recurrence (Ri1) at 12mo with most exhibiting activity at 3 years.
  - Clinical recurrence occurs much later<sup>1</sup>
- ~46% of CD patients require surgery within 10 years of diagnosis (range is 36-86% 37.7 % rate for kids<sup>2,3</sup>
  - Lower rate of small bowel disease for colectomy but 20-40%
- Evidence for surgery first line in limited TI disease (LIRIC trial) may argue for more surgery<sup>4</sup>









1. Hamilton AL et al. JCC 2022;16(12):1797
2. Yamaomo et al. Exp Review Gastro Hep 2015;9(1):55-66
3. Spinelli et al W J Gastro 2011;17(27):3213
4. Stevens TW et al. Lancet Gastroenterol Hep 2020;5(10):900-907



# Endoscopy: our gold standard


- Rutgeert's score developed in the 1990s – limited to disease proximal to the anastomotic inlet – designed for END to END anast (not side to side)

i0	i1	i2		i3	i4
		i2a	i2b		
					
No lesion in distal ileum	≤5 Aphthous lesions	Lesions confined to ileocolonic anastomosis	>5 Aphthous lesions with normal mucosa between the lesions	Diffuse aphthous ileitis with diffusely inflammed mucosa	Diffuse inflammation with already large ulcers and/or narrowing



# CT & MR – useful?

- 11 studies, 589 patients (4CTE, 7MRE)
- **MRE** pooled sens & spec were 90% (95%CI 0.78-0.96) and 78% (95%CI 0.57-0.90) respectively
- **CTE** pooled sens & spec were 93% (95%CI 0.87-0.96) and 67% (95%CI 0.35-0.90) respectively
- Most sens & spec parameters: **wall thickening**, penetrating lesions<sup>1</sup>
- **Colonic disease?** \*\*\*




Chavoshi et al. Abdom Radiol (NY). 2024; June3  
doi: 10.1007/s00261-024-04394-6.



# Biomarkers

- CRP and ESR insensitive for detecting POR<sup>1</sup>
- FC levels are higher in those with endoscopic disease activity compared to those in remission with good correlation with the Rutgeert's score<sup>2</sup>
- ECCO guidelines recommend FC measure 3mo post op with endoscopy guided by the level<sup>3</sup>




1. Yamaomo et al. Exp Review Gastro Hep 2015;9(1):55-66

2. Boschetti et al. Official J of College of Gastro, ACG. 2015;10(6):865-872.

3. Dragoni et al. JCC 2023;17(9):1373-1386.

# Success?


- Retrospective USA study, 901 post op CD patients, at least 1 yr after OR (2009-2019)<sup>1</sup>
  - Biomarkers (FC, CRP), imaging & IC (Rutgeert's  $\geq 2b$ )
- 78% considered high risk (HR), 28% 2 or more surgeries
- 38.1% of HR had monitoring w IC within 1yr











Neoterminal ileum  
BWT

staples

Colon  
Normal BWT

Narrowed inlet

Neo-terminal ileum

Bowel wall thickness measure, 1cm from the inlet

Colon - BWT

Anastomotic Inlet

Staples


Ileocolic anastomosis

Stool/  
air

Muscularis propria ▲



Submucosa ◆

Mucosa ●





[2D]  
Pen1  
Gn 60  
DR 104  
FA 5  
P 90%



TI AX


S

Wall thickness NTI


Neoterminal ileum (NTI)

Inlet - side to end anastomosis

Air shadowing










Acc

- S
- P
- F
- C
- S



% CI

h

Rispo et al.  
Inflamm Bowel  
Dis 2018;24(5):977

FIGURE 3. Summary receiver operating characteristic plot presenting test performance of US in detecting postsurgical recurrence.

**Table 3.** Diagnostic Accuracy of Noninvasive Parameters Alone or in Combination in Detecting Endoscopic Recurrence (95% CI): Per-patient Analysis


	Sensitivity, % (95% CI)	Specificity, % (95% CI)	Accuracy, % (95% CI)	PPV, % (95% CI)	NPV, % (95% CI)
BWT $\geq$ 3 mm	77 (64–87)	65 (45–81)	73 (62–81)	81 (68–90)	59 (41–75)
FC $\geq$ 50 mcg/g	83 (70–91)	64 (44–81)	76 (65–85)	81 (68–90)	67 (46–83)
Presence of lymph nodes	35 (23–48)	97 (83–100)	56 (45–66)	95 (77–100)	43 (32–56)
BWT $\geq$ 3 mm and FC $\geq$ 50 mcg/g	65 (51–78)	93 (76–99)	75 (64–84)	94 (81–99)	59 (43–74)
BWT $\geq$ 3 mm and FC $\geq$ 50 mcg/g and lymph nodes	33 (20–48)	100	66 (55–75)	100	59 (47–70)
BWT $\geq$ 3 mm or FC $\geq$ 50 mcg/g	93 (83–98)	34 (18–54)	74 (63–83)	74 (63–84)	71 (42–92)
BWT $\geq$ 3 mm or FC $\geq$ 50 mcg/g or lymph nodes	97 (88–100)	34 (18–54)	76 (66–85)	75 (64–84)	83 (52–98)

# Principles?


- Finding the anastomosis can be a treasure hunt – it doesn't need to be; nor should the disease distribution be a mystery.
- REVIEW the operative report
- REVIEW prior imaging
- R-hemi: anast will be HIGH in the RUQ; ileocecectomy – RLQ









**A. Side-to-side Isoperistaltic ileocolic anastomosis**



**B. Side-to-side antiperistaltic ileocolic anastomosis**



***Side-to-side antiperistaltic  
ileocolic anastomosis***



***Side-to-side isoperistaltic  
ileocolic anastomosis***

*Areas of interest for endoscopic follow-up are reported in different colors.*

	Ileal body		Neo-terminal ileum
	Anastomotic line		Ileal inlet
	Colonic blind loop		Ileal blind loop

# Case 1. MP

MP is a 28yo man with structuring ileal CD (Montreal classification A2 (diagnosed 18yrs), L1 (limited to the TI) and B3 (structuring in the absence of perianal disease

Non-smoker

Started on IFX monotherapy and treated with escalating doses to target optimal drug level.

BOWEL 1

C9-2

56Hz

R1

2D

43%

Dyn R 55


P Low

HRes

TIS0.2


MI 1.3

M4



\*\*\* bpm





# Case 2. MP



Post-operatively we restarted IFX

Felt extremely well, is vigilant with his eating (eating "clean"), fit, active and as no symptoms (HBI = 0)

Follows up to discuss stopping IFX given recurrent viral infections

Blood work:

Ferritin is 18, Hb 142 MCV 85, plt 287, WBC 6.1

Cr, liver enzymes normal

Fecal cal: pending




CA3-10A / Abdomen / FPS34 / MI1.1 / TIs0.3 / 2022-08-24 09:30:31 AM  
2D G44/DR35/FA10/P90/Frq Res./7.0cm






CA3-10A / Abdomen / FPS34 / MI1.1 / TIs0.3 / 2022-08-24 09:30:31 AM

2D G44/DR35/FA10/P90/Frq Res./7.0cm




CA3-10A / Abdomen / FPS34 / MI1.1 / TIs0.3 / 2022-08-24 09:30:31 AM

D G44/DR35/FA10/P90/Frq Res./7.0cm



CA3-10A / Abdomen / FPS34 / MI1.1 / TIs0.3 / 2022-08-24 09:27:54 AM  
2D G44/DR35/FA10/P90/Frq Res./7.0cm








CA3-10A / Abdomen / FPS11 / MI1.3 / TIs0.5 / 2022-08-24 09:31:46 AM


2D G44/DR35/FA10/P90/Frq Res./7.0cm

C G72/0.37kHz/F1/FA6















## Case 2. SH

78yo woman, active smoker, longstanding terminal ileal CD -  
Montreal class A2 L1 B3, absence of perianal disease

Resection while on IFX (2015) given progressive TI structuring  
disease – rough course post-operatively with an ileus, no leak  
no return to OR

Post op failed IFX, tried ADA (joint pain, neuropathy D/C), UST –  
nonresponse and now on VDZ q4weekly

Pain is her main complaint – no obstructive Sx, is best on  
steroids which we negotiate!

CA3-10A / Abdomen / FPS34 / MI1.1 / TIs0.3 / 2021-06-17 11:09:14 AM

2D G46/DR35/FA10/P90/Frq Res./7.0cm





CA3-10A / Abdomen / FPS34 / MI1.1 / IIs0.3 / 2021-06-17 / 11:02:49 AM


2D G46/DR35/FA10/P90/Frq Res./7.0cm



CA3-10A / Abdomen / FPS11 / MI1.3 / IIs0.6 / 2021-06-17 11:07:42 AM

2D G46/DR35/FA10/P90/Frq Res./7.0cm

C G56/0.55kHz/F1/FA6









# Case 3.

- 28yo male to female transgendered woman, very complex, Dx w ileocolonic disease at 11 w severe perianal involvement. Prior ilecectomy more than 8 years ago.
- Multiple hospital admissions to address severe perianal disease ultimately with diversion (left sided colostomy).
- Prior exposure to IFX, ADA, now on UST dosed q4 weekly
- “frozen abdomen” after last OR – had multiple challenges with small bowel obstruction post op (“hostile”).
- Scheduled for repeat colon, given poor prep, restage/grade disease post op.











Desc colon





SAMSUNG

CA3-10A / BOWEL GEN / FR38Hz

MI 0.98

2023-03-22

TIs 0.3

08:57:04 AM

2D G46/DR35/FA10/P90/Frq Res./6.0cm



SAMSUNG

CA3-10A / BOWEL GEN / FR38Hz


MI 0.98

2023-03-22

TIs 0.3

08:57:35 AM

2D G46/DR35/FA10/P90/Frq Res./6.0cm




Desc colon

D1 4.9 mm

















C. *End-to-end ileocolic anastomosis*



**A**



***End-to-end ileocolic anastomosis***




***Kono-S ileocolic anastomosis***


*Areas of interest for endoscopic follow-up are reported in different colors.*

	Ileal body		Neo-terminal ileum
	Anastomotic line		Ileal inlet
	Colonic blind loop		Ileal blind loop






**End-to-side ileocolic anastomosis**




**Side-to-end ileocolic anastomosis B**

*Areas of interest for endoscopic follow-up are reported in different colors.*

	Ileal body		Neo-terminal ileum
	Anastomotic line		Ileal inlet
	Colonic blind loop		Ileal blind loop





Chaves Oliverira E,  
Open Access Peer  
Reviewed Chapter

Current Elective  
Surgical Treatment  
Of IBD

Oct 2021

**Figure 8.**

The Heineke-Mikulicz technique. A - Longitudinal incision; B - transverse suture; C - final aspect.

CA3-10A / Abdomen / FPS34 / MI1.1 / TIs0.3 / 2022-08-26 12:26:25 PM  
2D G46/DR35/FA10/P90/Frq Res./7.0cm





# Case 4. JR

54 yo Norweigen Canadian man with longstanding ileal CD, surgery for a progressive, symptomatic stricture approximately 9d ago.

Presents to 'flare clinic' at the UofC during COVID

Can not stand up straight, abdominal pain, distention – waking him from sleep, no blood work available since OR/ admission.


CA3-10A / Abdomen / FPS36 / MI1.1 / IIs0.4 / 2020-09-15 09:11:24 AM  
2D G46/DR35/FA10/P90/Frq Res./7.0cm



CA3-10A / Abdomen / FPS14 / MI1.3 / TIs0.8 / 2020-09-15 09:14:07 AM

2D G46/DR35/FA10/P90/Frq Res./7.0cm

C G56/0.74kHz/F1/FA6





# Case 6. AC

34 yo Engineer, longstanding, stricturing terminal ileal CD, no Luminal penetrating complications, no perianal disease, non-smoker.

Long segment of TI affected, continues to have pain in the RLQ post operatively, significant diarrhea with some improvement with bile-acid sequestration.

OR was complicated by a intra-operative

Bowel1 / LA2-14A / 6.5cm / 36Hz   

Tls 0.2 / Tlb 0.2 / MI 1.2

[2D]

Pen1


Gn 65

DR 104

FA 5

P 90%

S

0  
-  
1  
-  
2  
-  
3  
-  
4  
-  
5  
-  
6  
-

ANAST

## Case 7. GH

38yo father of 4, 12 years of complex penetrating ileal CD

Resection July 2016 – 6 weeks post-op very sudden (within 24hr) onset severe bloating/ fullness, loss of appetite and intermittent severe peri-umbilical belly pain

Sough pain relief from GP – now needing opiates

Non-smoker



## Case 7. GH

Blood work completed post operatively demonstrated anemia,  
Hb 118 with MCV 92

CRP 2.1

No fecal calprotectin available

BOWEL 1

C9-2

45Hz

R1

2D

48%

Dyn R 55

P Low

HRes

TIS0.2 MI 1.3

M4



\*\*\* bpm

BOWEL 1

C9-2

50Hz

R1

2D

44%

Dyn R 55

P Low

HRes


TIS0.2 MI 1.3

M4




\*\*\* bpm







# Personalized Pre-operative RISK STRATIFICATION





# Thank you



[knovak@ucalgary.ca](mailto:knovak@ucalgary.ca)